Esperion Therapeutics (ESPR) Receivables (2020 - 2026)

Esperion Therapeutics has reported Receivables for 7 years, with the latest figure at $132.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 62.81% year-over-year to $132.4 million; the trailing twelve-month figure through Mar 2026 stood at $132.4 million (up 62.81% YoY), and the FY2025 full-year result was $140.2 million, up 74.93% from the prior year.
• Receivables for Q1 2026 stood at $132.4 million, down from $140.2 million in the prior quarter.
• The five-year high for Receivables was $140.2 million in Q4 2025, with the low at $25.1 million in Q1 2022.
• Historically, Receivables has averaged $66.5 million across 5 years, with a median of $54.6 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables rose 12.86% — and 2025, when it soared 78.51%.
• Esperion Therapeutics' Receivables stood at $33.7 million in 2022, then surged by 43.78% to $48.5 million in 2023, then jumped by 65.26% to $80.1 million in 2024, then surged by 74.93% to $140.2 million in 2025, then retreated by 5.59% to $132.4 million in 2026.
• The last three Receivables figures came in at $132.4 million (Q1 2026), $140.2 million (Q4 2025), and $119.0 million (Q3 2025), per Business Quant data.